摘要
目的综合评价分别应用吉非替尼(gefitinib)与培美曲塞(pemetrexed)两种方案治疗晚期非小细胞肺癌(NSCLC)患者的临床效果。方法在选定的数据库中使用关键词搜索关于吉非替尼对比培美曲塞两种药物方案治疗晚期NSCLC的文献,提取相关研究数据,采用Rev Man5.3软件进行数据分析比较。结果符合条件的关于吉非替尼对比培美曲塞临床疗效的中英文文献共9个。吉非替尼与培美曲塞治疗晚期NSCLC的有效率的风险比(RR)值为1.00(P=0.99>0.05),疾病控制率的RR值为0.98(P=0.77>0.05)。结论吉非替尼与培美曲塞两种方案治疗晚期NSCLC的疗效无统计学差异,但仍需要更多高质量的大规模随机对照研究来进一步研究。
Objective To systematically evaluate the efficacy of gefitinib and pemetrexed in patients with non -small cell lung cancer （NSCLC）. Methods The related literature concerning the clinical trials of gefitinib and pemetrexed in the treatment of non - small cell lung cancer published both in the domestic area and overseas literature. Meta analysis of the selected literature was conducted by means of Review Manager 5.3 software. Results A total of 9 clinical trials were included in our study. The risk rate （RR） of ge fitinib and pemetreted treating NSCLC is 1.00 （P = 0. 99 〉 0. 55 ）, RR of disease controlo rate is 0. 98 （ P = 0. 77 〉 0. 05 ）. Conclusion No profound significant differences were found in efficacy between gefitinib and pemetrexed in patients with NSCLC. However, the More higher quality studies are needed to further prove the results.
出处
《河南外科学杂志》
2017年第3期1-5,共5页
Henan Journal of Surgery
